These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36991240)

  • 21. Is "unilateral" moyamoya disease different from moyamoya disease?
    Houkin K; Abe H; Yoshimoto T; Takahashi A
    J Neurosurg; 1996 Nov; 85(5):772-6. PubMed ID: 8893713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indirect revascularization with the dural inversion technique for pediatric moyamoya disease: 20-year experience.
    Gadgil N; Lam S; Pyarali M; Paldino M; Pan IW; Dauser RC
    J Neurosurg Pediatr; 2018 Nov; 22(5):541-549. PubMed ID: 30117790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarker research for moyamoya disease in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    Maruwaka M; Yoshikawa K; Okamoto S; Araki Y; Sumitomo M; Kawamura A; Yokoyama K; Wakabayashi T
    J Stroke Cerebrovasc Dis; 2015 Jan; 24(1):104-11. PubMed ID: 25440344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SDF-1/CXCR4 axis participants in the pathophysiology of adult patients with moyamoya disease.
    Ren S; Han Q; Zhou P; Wang Z; Huang Y
    J Stroke Cerebrovasc Dis; 2024 Jun; 33(6):107717. PubMed ID: 38608825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease.
    Kim SK; Yoo JI; Cho BK; Hong SJ; Kim YK; Moon JA; Kim JH; Chung YN; Wang KC
    Stroke; 2003 Dec; 34(12):2835-41. PubMed ID: 14605320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early manifestation of Moyamoya syndrome in a 2-year-old child with Down syndrome.
    Tajmalzai A; Shirzai A; Najah DM
    Radiol Case Rep; 2021 Jul; 16(7):1740-1744. PubMed ID: 34007395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basal meningoencephalocele, anomaly of optic disc and panhypopituitarism in association with moyamoya disease.
    Komiyama M; Yasui T; Sakamoto H; Fujita K; Sato T; Ota M; Sugita M
    Pediatr Neurosurg; 2000 Aug; 33(2):100-4. PubMed ID: 11070437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unilateral hemispheric proliferation of ivy sign on fluid-attenuated inversion recovery images in moyamoya disease correlates highly with ipsilateral hemispheric decrease of cerebrovascular reserve.
    Kawashima M; Noguchi T; Takase Y; Ootsuka T; Kido N; Matsushima T
    AJNR Am J Neuroradiol; 2009 Oct; 30(9):1709-16. PubMed ID: 19713323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebral blood flow findings in moyamoya disease in adults.
    Dietrichs E; Dahl A; Nyberg-Hansen R; Russell D; Rootwelt K; Veger T
    Acta Neurol Scand; 1992 May; 85(5):318-22. PubMed ID: 1621493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Panel of Exosome-Derived miRNAs of Cerebrospinal Fluid for the Diagnosis of Moyamoya Disease.
    Wang G; Wen Y; Faleti OD; Zhao Q; Liu J; Zhang G; Li M; Qi S; Feng W; Lyu X
    Front Neurosci; 2020; 14():548278. PubMed ID: 33100957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of and risk factors for enlarged perivascular spaces in adult patients with moyamoya disease.
    Kuribara T; Mikami T; Komatsu K; Suzuki H; Ohnishi H; Houkin K; Mikuni N
    BMC Neurol; 2017 Aug; 17(1):149. PubMed ID: 28778183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response profiling identifies autoantibodies specific to Moyamoya patients.
    Sigdel TK; Shoemaker LD; Chen R; Li L; Butte AJ; Sarwal MM; Steinberg GK
    Orphanet J Rare Dis; 2013 Mar; 8():45. PubMed ID: 23518061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moyamoya-like vasculopathy in neurosarcoidosis.
    Ko JK; Lee SW; Choi CH
    J Korean Neurosurg Soc; 2009 Jan; 45(1):50-2. PubMed ID: 19242573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of Fibroblasts Into Myofibroblasts in the Arachnoid Membrane of Moyamoya Disease.
    Yamamoto S; Yamamoto S; Akai T; Sasahara M; Kuroda S
    Stroke; 2022 Nov; 53(11):3465-3473. PubMed ID: 36039752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leptomeningeal high signal intensity (ivy sign) on fluid-attenuated inversion-recovery (FLAIR) MR images in moyamoya disease.
    Fujiwara H; Momoshima S; Kuribayashi S
    Eur J Radiol; 2005 Aug; 55(2):224-30. PubMed ID: 16036151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrohistory of Moyamoya Disease Analyzed Using Artificial Intelligence.
    Kuribara T; Akiyama Y; Mikami T; Komatsu K; Kimura Y; Takahashi Y; Sakashita K; Chiba R; Mikuni N
    Cerebrovasc Dis; 2022; 51(4):413-426. PubMed ID: 35104814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease.
    Yamamoto M; Aoyagi M; Tajima S; Wachi H; Fukai N; Matsushima Y; Yamamoto K
    Stroke; 1997 Sep; 28(9):1733-8. PubMed ID: 9303017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease.
    Wang G; Wen Y; Chen S; Zhang G; Li M; Zhang S; Qi S; Feng W
    CNS Neurosci Ther; 2021 Aug; 27(8):908-918. PubMed ID: 33942536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Genetic Variants with Postoperative Donor Artery Development in Moyamoya Disease: RNF213 and Other Moyamoya Angiopathy-Related Gene Analysis.
    Torazawa S; Miyawaki S; Imai H; Hongo H; Ono H; Ogawa S; Sakai Y; Kiyofuji S; Koizumi S; Komura D; Katoh H; Ishikawa S; Saito N
    Transl Stroke Res; 2024 Apr; ():. PubMed ID: 38592555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moyamoya Syndrome: A Window of Moyamoya Disease.
    Phi JH; Wang KC; Lee JY; Kim SK
    J Korean Neurosurg Soc; 2015 Jun; 57(6):408-14. PubMed ID: 26180607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.